Sensorion Provides Preliminary Documents for the Combined Sh

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company's shareholders

Related Keywords

Paris , France General , France , French , David Lawrence , Square Louvois , Institut Pasteur , Communications Europe France , Consilium Strategic Communications , International Media Relations , Regulatory News , Combined General Meeting , French Commercial Code , General Meeting , Annual General Meeting , Combined Shareholder General Meeting , Cisplatin Induced Ototoxicity , Cochlear Limited , Sudden Sensorineural Hearing Loss , Chief Financial Officer , United Kingdom , Investor Relations , Strategic Communications , Sue Stuart , Sensorion , Rovides , Reliminary , Documents , Combined , Shareholders , Eneral , Meeting , 023 ,